CDRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cadre Holdings Inc (CDRE) is not a clear buy right now for a Beginner investor focused on long-term holding with $50,000-$100,000 to deploy. The stock is showing some near-term strength, but the longer-term trend is still technically mixed and the latest analyst target cuts suggest the Street is becoming more cautious. Since the user is inpatient and does not want to wait for a better entry, my direct view is to avoid buying today and wait for a cleaner setup. It is not a strong buy at current levels.
CDRE closed at 30.96, up 4.81% on the session, which shows short-term momentum. MACD histogram is positive and expanding, indicating improving momentum. RSI_6 at 60.29 is neutral to mildly bullish, not overbought. However, the moving average structure is still bearish with SMA_200 > SMA_20 > SMA_5, which means the longer trend remains weak despite the recent bounce. Price is trading just above pivot support at 30.385 and below resistance at 31.505, so the stock is still in a recovery phase rather than a confirmed uptrend. The technical picture is mixed, leaning cautious.
Recent analyst commentary still keeps Buy ratings on the stock, and both Roth Capital and Jefferies pointed to the long-term story remaining intact. Roth highlighted sound Q1 results, in-line sales, and adjusted EBITDA ahead of low expectations, while also citing TYR acquisition benefits and blast monitoring sensor ramp-up as support for stronger second-half performance. Congress trading data is also supportive, with 1 purchase and 0 sales in the last 90 days, indicating at least some positive political interest. Similar-pattern stock analysis suggests potential upside over the next month.
No fresh news was reported in the last week, so there is no immediate event-driven catalyst. Analyst price targets were cut from $45 to $40 by both Roth Capital and Jefferies, showing reduced near-term expectations. Jefferies also noted shares fell 10% after revenue and EBITDA only slightly beat estimates while EPS missed due to M&A costs. The technical trend remains bearish on the moving averages, and hedge funds and insiders are both neutral with no significant buying trend.
Latest quarter financials are not fully available due to a data error, but the analyst notes provide a useful snapshot for the latest quarter, Q1 2026. Q1 sales were in line and adjusted EBITDA was ahead of relatively low expectations, which is positive. However, EPS missed by 5c according to Jefferies, with about a 6c headwind from M&A costs. The commentary suggests the quarter was decent operationally but not strong enough to reset expectations higher. Growth looks supported by acquisition-related activity and product ramp-up, but near-term financial consistency remains choppy.
Analyst sentiment is still bullish overall, but targets are being trimmed. Roth Capital cut its target to $40 from $45 and kept Buy, and Jefferies cut to $40 from $45 while also keeping Buy. Earlier in March, Jefferies reduced its target to $45 from $55 after a weak Q4 and said the long-term story remained intact. Wall Street pros view: the positive side is that multiple firms still recommend Buy and believe the core thesis is intact; the negative side is that estimates are being lowered, near-term fundamentals are uneven, and recent earnings have disappointed enough to pressure the stock.
